What is Apomorphine

Parkinson’s disease is a chronic and progressive degenerative disease of the brain that impairs motor control, speech, and other functions.

APO-go (apomorphine hydrochloride) provides rapid reversal of the symptoms of complex Parkinson’s disease and belongs to medications in the class of dopamine agonists, which directly stimulate dopamine receptors.

Apomorphine therapies

Marketed as APO-go in the UK and certain EU countries, Apokyn in the US, Apomine in Australia and Apokinon in France, it is available as an intermittent injection or via continuous infusion through Britannia’s growing network of distribution partners.

APO-go is a highly effective1, 2 anti-parkinsonian drug that is a direct stimulant of dopamine receptors. APO-go possesses both D1 and D2 receptor agonist properties, resulting in a magnitude of response comparable to levodopa, and substantially greater than other dopamine agonists. Although derived from morphine it has no opiate or direct pain-killing properties and is not a controlled drug.

"Off" period prevention

APO-go will restore mobility and prevent ‘off’ periods, within four to twelve minutes of treatment.4 The injectable nature of APO-go and resultant high bioavailability ensure that it acts very rapidly to treat the debilitating effects of Pd.

APO-go is derived from morphine but is not an opiate and does not possess the narcotic properties associated with morphine.

1. Pietz K, Hagell P, Odin P, 1998. Subcutaneous apomorphine in late stage Parkinson’s disease: A long term follow up. Journal of Neurology Neurosurgery and Psychiatry, 65:709–716.

2.Lees A, Turner K, 2002. Apomorphine for Parkinson’s Disease. Practical Neurology, 2:280-287.
3.Hagell P, Odin P 2001. Apomorphine in the treatment of Parkinson’s disease. Journal of Neuroscience Nursing, 9(33):No.1.
4. APO-go SmPC 2012.

Our Partners